Corcept Therapeutics (CORT) Misses Q4 EPS by 5c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.71 --0%
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.20, $0.05 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $202.12 million versus the consensus estimate of $249.52 million.
GUIDANCE:
Corcept Therapeutics sees FY2026 revenue of $0.9-1 billion, versus the consensus of $0.96 billion.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- Keurig Dr Pepper coffee chief to depart ahead of planned split
- Jefferies Reinstates Talen Energy (TLN) at Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
